PE20230112A1 - Formulaciones de anticuerpos anti-tslp humanos y metodos de tratamiento de una enfermedad inflamatoria - Google Patents
Formulaciones de anticuerpos anti-tslp humanos y metodos de tratamiento de una enfermedad inflamatoriaInfo
- Publication number
- PE20230112A1 PE20230112A1 PE2022001741A PE2022001741A PE20230112A1 PE 20230112 A1 PE20230112 A1 PE 20230112A1 PE 2022001741 A PE2022001741 A PE 2022001741A PE 2022001741 A PE2022001741 A PE 2022001741A PE 20230112 A1 PE20230112 A1 PE 20230112A1
- Authority
- PE
- Peru
- Prior art keywords
- methods
- inflammatory disease
- tslp antibody
- treatment
- human anti
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 159000000007 calcium salts Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 159000000003 magnesium salts Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En la presente se proporcionan composiciones acuosas que comprenden (a) un anticuerpo anti-TSLP a una concentracion mayor que aproximadamente 140 mg/ml, (b) un tensioactivo y (c) al menos un aminoacido basico o una sal del mismo. Tambien se proporcionan composiciones acuosas que comprenden composiciones acuosas que comprenden (a) un anticuerpo anti-TSLP a una concentracion mayor que aproximadamente 140 mg/ml, (b) un tensioactivo y (c) al menos una sal de calcio o sal de magnesio. Tambien se proporcionan articulos de fabricacion relacionados, jeringas precargadas y viales que comprenden las composiciones de la presente divulgacion. Se proporcionan en la presente usos de las composiciones para tratar una enfermedad inflamatoria, por ejemplo, la dermatitis atopica. Ademas, se proporcionan en la presente metodos de preparacion de un anticuerpo estable y liquido que tiene una viscosidad de menos de aproximadamente 100 cP.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976007P | 2020-02-13 | 2020-02-13 | |
| US202163148105P | 2021-02-10 | 2021-02-10 | |
| PCT/US2021/017880 WO2021163504A1 (en) | 2020-02-13 | 2021-02-12 | Formulations of human anti-tslp antibodies and methods of treating inflammatory disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230112A1 true PE20230112A1 (es) | 2023-01-27 |
Family
ID=74858823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001741A PE20230112A1 (es) | 2020-02-13 | 2021-02-12 | Formulaciones de anticuerpos anti-tslp humanos y metodos de tratamiento de una enfermedad inflamatoria |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230078678A1 (es) |
| EP (1) | EP4103235A1 (es) |
| JP (1) | JP2023513312A (es) |
| KR (1) | KR20220140772A (es) |
| CN (1) | CN115279404A (es) |
| AU (1) | AU2021219839A1 (es) |
| BR (1) | BR112022016010A2 (es) |
| CA (1) | CA3166964A1 (es) |
| CL (1) | CL2022002193A1 (es) |
| CO (1) | CO2022012868A2 (es) |
| CR (1) | CR20220457A (es) |
| IL (1) | IL295042A (es) |
| JO (1) | JOP20220183A1 (es) |
| MX (1) | MX2022010012A (es) |
| PE (1) | PE20230112A1 (es) |
| PH (1) | PH12022552050A1 (es) |
| UY (1) | UY39083A (es) |
| WO (1) | WO2021163504A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3142545A1 (en) | 2019-06-04 | 2020-12-10 | Jiangsu Hengrui Medicine Co., Ltd. | Antibody capable of binding to thymic stromal lymphopoietin and use thereof |
| TWI891945B (zh) * | 2020-12-03 | 2025-08-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 抗tslp抗體藥物組合物及其用途 |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| WO2025082377A1 (zh) * | 2023-10-17 | 2025-04-24 | 江苏恒瑞医药股份有限公司 | 一种抗tslp抗体的药物组合物及其用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| WO2011056772A1 (en) | 2009-11-04 | 2011-05-12 | Schering Corporation | Engineered anti-tslp antibody |
| TWI505838B (zh) * | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
| SMT202000095T1 (it) * | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| AR082163A1 (es) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| EP3209332B1 (en) * | 2014-10-23 | 2021-05-26 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| AR103891A1 (es) | 2015-03-11 | 2017-06-14 | Glaxosmithkline Ip Dev Ltd | Proteínas de unión a tslp, ácido nucleico aislado que la codifica, vector y célula hospedadora que lo comprenden, método para producir dicha proteína, su uso para fabricar un medicamento, composición farmacéutica y kit que la comprenden |
| TN2018000076A1 (en) | 2015-09-09 | 2019-07-08 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules |
| TWI836745B (zh) * | 2015-12-18 | 2024-03-21 | 美商上游生物公司 | 含有抗人類ｔｓｌｐ受體抗體之醫藥組成物 |
| JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
| MA48461A (fr) * | 2017-04-28 | 2020-03-04 | Amgen Inc | Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation |
| US11904143B2 (en) | 2017-06-08 | 2024-02-20 | Amgen Inc. | Torque driven drug delivery device |
| BR112020001203A2 (pt) * | 2017-07-27 | 2020-07-28 | Jiangsu Hengrui Medicine Co., Ltd. | composição farmacêutica de anticorpo sost e usos da mesma |
| MX2020004736A (es) | 2017-11-10 | 2020-08-13 | Amgen Inc | Embolos para dispositivos de administracion de farmacos. |
| EP4321870B1 (en) | 2018-03-13 | 2025-07-30 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| MX2021002791A (es) | 2018-10-15 | 2021-05-12 | Amgen Inc | Proceso de ensamblaje de plataforma para un dispositivo de administracion de farmacos. |
| US12053617B2 (en) | 2018-10-15 | 2024-08-06 | Amgen Inc. | Drug delivery device having damping mechanism |
| JP7670713B2 (ja) * | 2019-12-05 | 2025-04-30 | サノフィ－アベンティス・ユー・エス・エルエルシー | 皮下投与のための抗ｃｄ３８抗体の製剤 |
-
2021
- 2021-02-12 AU AU2021219839A patent/AU2021219839A1/en active Pending
- 2021-02-12 JP JP2022548653A patent/JP2023513312A/ja active Pending
- 2021-02-12 PH PH1/2022/552050A patent/PH12022552050A1/en unknown
- 2021-02-12 CA CA3166964A patent/CA3166964A1/en active Pending
- 2021-02-12 KR KR1020227030979A patent/KR20220140772A/ko active Pending
- 2021-02-12 BR BR112022016010A patent/BR112022016010A2/pt unknown
- 2021-02-12 IL IL295042A patent/IL295042A/en unknown
- 2021-02-12 CN CN202180017163.9A patent/CN115279404A/zh active Pending
- 2021-02-12 MX MX2022010012A patent/MX2022010012A/es unknown
- 2021-02-12 US US17/760,427 patent/US20230078678A1/en active Pending
- 2021-02-12 PE PE2022001741A patent/PE20230112A1/es unknown
- 2021-02-12 EP EP21710162.5A patent/EP4103235A1/en active Pending
- 2021-02-12 WO PCT/US2021/017880 patent/WO2021163504A1/en not_active Ceased
- 2021-02-12 JO JOP/2022/0183A patent/JOP20220183A1/ar unknown
- 2021-02-12 UY UY0001039083A patent/UY39083A/es unknown
- 2021-02-12 CR CR20220457A patent/CR20220457A/es unknown
-
2022
- 2022-08-12 CL CL2022002193A patent/CL2022002193A1/es unknown
- 2022-09-09 CO CONC2022/0012868A patent/CO2022012868A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021163504A1 (en) | 2021-08-19 |
| KR20220140772A (ko) | 2022-10-18 |
| EP4103235A1 (en) | 2022-12-21 |
| CN115279404A (zh) | 2022-11-01 |
| IL295042A (en) | 2022-09-01 |
| BR112022016010A2 (pt) | 2022-12-20 |
| JOP20220183A1 (ar) | 2023-01-30 |
| CA3166964A1 (en) | 2021-08-19 |
| MX2022010012A (es) | 2022-09-07 |
| AU2021219839A1 (en) | 2022-08-25 |
| CO2022012868A2 (es) | 2022-12-09 |
| CR20220457A (es) | 2023-01-09 |
| JP2023513312A (ja) | 2023-03-30 |
| US20230078678A1 (en) | 2023-03-16 |
| PH12022552050A1 (en) | 2024-02-12 |
| UY39083A (es) | 2021-08-31 |
| CL2022002193A1 (es) | 2023-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230112A1 (es) | Formulaciones de anticuerpos anti-tslp humanos y metodos de tratamiento de una enfermedad inflamatoria | |
| AR105712A1 (es) | Composiciones de insulina de rápida acción | |
| AR107014A1 (es) | Formulación farmacéutica acuosa | |
| BR112012022223A8 (pt) | Formulação de proteína concentrada, uso e método de preparação da mesma | |
| GT201700096A (es) | Formulación estable de proteína en solución que contiene una alta concentración de un anticuerpo anti-vegf | |
| AR109494A1 (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos | |
| AR040881A1 (es) | Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-alfa | |
| BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
| BR112015022896A2 (pt) | drogas de alta penetração e suas composições para o tratamento de doenças de parkinson | |
| BR112014028600A8 (pt) | Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação | |
| BR112013027674A2 (pt) | "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha". | |
| MX2015015152A (es) | Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13. | |
| WO2017131130A1 (ja) | コンドロイチン硫酸及びヒアルロン酸を含有する安定化された水性組成物 | |
| CO2021007830A2 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| AR115713A1 (es) | FORMULACIÓN ESTABLE DE ALTA CONCENTRACIÓN PARA ANTICUERPOS ANTI-FXIa | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| AR107212A1 (es) | Compuestos tópicos de matriz polimérica que comprenden una alta concentración de hialuronato de sodio biofermentado y sus usos | |
| AR039895A1 (es) | Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla | |
| AR121329A1 (es) | Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria | |
| CO2023002650A2 (es) | Formas farmacéuticas sólidas de palbociclib | |
| CL2025000209A1 (es) | Formulación farmacéutica estable líquida oral de un agente antiespasmódico | |
| BR112022004836A2 (pt) | Processo para preparar um hidrogel super poroso plastificado, uso de um ou mais hidrogéis super porosos plastificados e formulação de dosagem oral | |
| MX2020012728A (es) | Medicinas de origen biologico y metodos para incrementar el cumplimiento del paciente. | |
| MX2024004656A (es) | Formulaciones acuosas de un anticuerpo anti-cd22 y usos de las mismas. |